Is There an Ozempic for Cats?
Short answer: not yet — but cats are the first animals being studied. Two separate feline GLP-1 trials are running right now. Here's what's real.
There is no FDA-approved GLP-1 medication — Ozempic, Wegovy, semaglutide, or otherwise — for cats as of April 2026. Veterinarians cannot legally prescribe human GLP-1 medications to cats. But unlike dogs, cats are now first in line: two separate clinical trials testing pet-specific GLP-1 drugs in cats are actively enrolling. Okava Pharmaceuticals' MEOW-1 trial tests an exenatide-releasing implant. Akston Biosciences' AKS-562c tests a once-weekly injection at Cornell University. Both report results in summer 2026.
Why cats first? Three reasons. (1) Feline obesity is reaching crisis levels — APOP's vet survey put US cat overweight/obesity prevalence at 61%, slightly higher than dogs. (2) Cats are notoriously hard to put on diets through food restriction alone — owners report severe behavioral problems and food-aggression when intake drops. A pharmaceutical option fits the species better. (3) Cats don't have the same pancreatitis breed-predisposition pattern as dogs, which lowers one of the regulatory barriers for GLP-1 trials.
What's Actually in Trials Right Now
Okava MEOW-1 — The Exenatide Implant
Okava Pharmaceuticals is developing OKV-119, a small subcutaneous implant designed to release exenatide (a GLP-1 receptor agonist originally approved for human diabetes) over approximately six months. The MEOW-1 trial — Management of Excess Overweight cats With OKV-119 — enrolls at least 50 cats. About two-thirds receive the active implant, the rest serve as controls. Owners observe their cats over a 3-month primary period with an optional 3-month extension. Trial initiation was December 2025; results are expected summer 2026, with FDA submission targeted for 2027-2028 and potential commercial launch around $100/month-equivalent retail pricing if approved.
Akston AKS-562c — The Weekly Injection at Cornell
Separate from Okava, Akston Biosciences is running a feline trial at the Cornell University College of Veterinary Medicine. Their candidate, AKS-562c, is a once-weekly GLP-1 Fc-fusion injection — a different molecule and a different delivery format from Okava's implant. The Cornell trial enrolls 70 cats with the option to expand to 140, over a roughly 3-month observation period. Akston announced trial initiation in November 2025.
Realistic Timeline
| Stage | Okava OKV-119 | Akston AKS-562c |
|---|---|---|
| Trial start | December 2025 | November 2025 |
| Cats enrolled | ≥50 | 70 (up to 140) |
| Primary observation | 3 months + 3 mo opt | ~3 months |
| Results expected | Summer 2026 | Mid-to-late 2026 |
| FDA submission | 2027-2028 | Not announced |
| Cat market launch | 2027-2028 (best case) | Not announced |
| Dog trial start | Not announced | Not announced |
| Realistic dog launch | 2028-2030 | 2028-2030 |
Even in a best-case scenario, no FDA-approved cat GLP-1 will be available before late 2027. Veterinary drug development from Phase 2 to FDA approval typically takes 2-3 years after positive trial readout, and that's assuming the trial succeeds.
Why Vets Won't Prescribe Human Ozempic to Your Cat
- Species-specific dosing has never been studied for cats. Human dosing scales by body weight, but GLP-1 receptor density and incretin response differ significantly between species. A 'safe' human dose could be sub-therapeutic — or unsafe — in a cat of any size.
- Hepatic lipidosis risk is elevated in cats with rapid weight loss. Cats who lose weight too fast develop fatty liver disease (hepatic lipidosis), which can be fatal. GLP-1 medications cause appetite suppression, and an off-label, untested dose could trigger weight loss faster than the cat's liver can adapt.
- Compounding pharmacies cannot legally fill a human-drug prescription for a cat without veterinary oversight, and most veterinarians won't write that script. FDA guidance for veterinary compounding restricts compounding for off-label species use without a clinical justification — and 'my cat is overweight' is not a clinical justification when food therapy is the standard of care.
What You Can Actually Do Right Now
- Confirm your cat is actually overweight. Use the 9-point Body Condition Score scale. Most owners overestimate or underestimate by 1-2 BCS points. A cat with BCS 6-7 is overweight; BCS 8-9 is obese.
- Switch to a vet-formulated weight management food. Hill's Metabolic, Royal Canin Satiety, and Purina OM all have feline-specific weight loss formulations with reduced calorie density and increased protein/fiber for satiety.
- Use a portion-controlled timed feeder. Cats don't self-regulate well with free-feeding. A timed automatic feeder splitting daily intake into 4-5 small meals helps prevent the food-aggression that crash diets cause.
- Add play exercise — 10-15 min twice daily. Wand toys, laser pointers, and food puzzles. Cats that play eat less and lose weight more steadily.
- Re-weigh monthly, not weekly. Cats should lose 0.5-2% of body weight per week. A 12-pound cat losing 0.5 pound per month is on track. Faster than that risks hepatic lipidosis.
Get Notified When Cat GLP-1 Launches
We track both cat trials and will send one email when the first cat GLP-1 medication becomes commercially available. No spam. No marketing emails. Single-purpose alert.
Frequently Asked Questions
Can I give my cat my Ozempic prescription?+
When will Ozempic for cats be available?+
How much will pet GLP-1 cost?+
What's the difference between Okava and Akston?+
Related
Veterinary disclaimer:This article is for informational purposes only and does not constitute veterinary advice. Always consult a licensed veterinarian before changing your pet's diet, exercise routine, or medication. Information is current as of the publication date but pet pharmaceutical and food formulation details may change.
Looking for human GLP-1 medications instead?
Visit GLP-1 Picks → 42 verified telehealth providers